Gary L Johnson
Overview
Explore the profile of Gary L Johnson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
162
Citations
6908
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Asquith C, East M, Laitinen T, Alamillo-Ferrer C, Hartikainen E, Wells C, et al.
bioRxiv
. 2024 Jan;
PMID: 38234837
The oxindole scaffold has been the center of several kinase drug discovery programs, some of which have led to approved medicines. A series of two oxindole matched pairs from the...
12.
Gomez S, Axtman A, Willson T, Major M, Townsend R, Sorger P, et al.
Drug Discov Today
. 2024 Jan;
29(3):103881.
PMID: 38218213
The human kinome, with more than 500 proteins, is crucial for cell signaling and disease. Yet, about one-third of kinases lack in-depth study. The Data and Resource Generating Center for...
13.
Joisa C, Chen K, Beville S, Stuhlmiller T, Berginski M, Okumu D, et al.
Pac Symp Biocomput
. 2023 Dec;
29:276-290.
PMID: 38160286
Protein kinases are a primary focus in targeted therapy development for cancer, owing to their role as regulators in nearly all areas of cell life. Recent strategies targeting the kinome...
14.
Joisa C, Chen K, Beville S, Stuhlmiller T, Berginski M, Okumu D, et al.
bioRxiv
. 2023 Aug;
PMID: 37577663
Protein kinases are a primary focus in targeted therapy development for cancer, owing to their role as regulators in nearly all areas of cell life. Kinase inhibitors are one of...
15.
Flint A, Mitchell D, Angus S, Smith A, Bessler W, Jiang L, et al.
Clin Cancer Res
. 2023 Jul;
29(17):3438-3456.
PMID: 37406085
Purpose: Plexiform neurofibromas (PNF) are peripheral nerve sheath tumors that cause significant morbidity in persons with neurofibromatosis type 1 (NF1), yet treatment options remain limited. To identify novel therapeutic targets...
16.
Murray N, Asquith C, Fang Z, East M, Ptak N, Smith R, et al.
Nat Chem Biol
. 2022 Oct;
19(2):230-238.
PMID: 36302899
Small-molecule tools have enabled mechanistic investigations and therapeutic targeting of the protein kinase-like (PKL) superfamily. However, such tools are still lacking for many PKL members, including the highly conserved and...
17.
Karim M, Saul S, Ghita L, Sahoo M, Ye C, Bhalla N, et al.
Antiviral Res
. 2022 Jun;
204:105367.
PMID: 35738348
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to pose serious threats to global health. We previously reported that AAK1, BIKE...
18.
Almeter P, Isaacs J, Hunter A, Henderson B, Platt T, Mitchell B, et al.
J Pharm Innov
. 2022 Jun;
17(2):269-282.
PMID: 35677914
Since the US Food and Drug Administration (FDA) began monitoring the quality of pharmaceutical manufacturing by enforcing current good manufacturing practices roughly 60 years ago, forces related to the global...
19.
Asquith C, Temme L, East M, Laitinen T, Pickett J, Kwarcinski F, et al.
ChemMedChem
. 2022 Apr;
17(12):e202200161.
PMID: 35403825
Deep annotation of a library of 4-anilinoquin(az)olines led to the identification of 7-iodo-N-(3,4,5-trimethoxyphenyl)quinolin-4-amine 16 as a potent inhibitor (IC =14 nM) of Protein Kinase Novel 3 (PKN3) with micromolar activity...
20.
East M, Johnson G
J Biol Chem
. 2021 Dec;
298(2):101525.
PMID: 34958800
Pharmacological inhibition of protein kinases induces adaptive reprogramming of tumor cell regulatory networks by altering expression of genes that regulate signaling, including protein kinases. Adaptive responses are dependent on transcriptional...